drugset / Trial / NCT03643107
Irofulven in AR-targeted and Docetaxel-Pretreated mCRPC Patients With Drug Response Predictor (DRP®)
Phase 2
Completed
15 enrolled
Allarity Therapeutics
Lantern Pharma Inc. · collabSmerud Medical Research International AS · collab
NaSingle-groupOpen-labelTreatment
Summary
The study seek to evaluate the anti-tumor effect after treatment of Irofulven in combination with prednisolone in patients who progressed on androgen receptor(AR)-targeted therapy and Docetaxel-Pretreated Metastatic Castration-Resistant Prostate Cancer Patients. A drug response predictor (DRP®) biomarker in prostate cancer patients will identify patients likely to respond to and benefit from treatment with Irofulven.
Timeline
- Start
- 2018-10-17
- Primary completion
- 2021-10-01
- Completion
- 2022-08-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | irofulven | Small molecule | 0.45 mg/kg | Intravenous |
| Background | Prednisolone | Other / unclassified | 10 mg | Oral |